Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

International Business Times

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

The Guardian - US

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

As Tesla stock continues to underperform - now down more than 22% year-to-date - here are 3 mega-cap companies worthy of replacing the beleaguered EV giant in the elite group of mega-cap stocks known as the Magnificent Seven.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

The Guardian - UK

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism

Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism

While the main indexes made modest moves Tuesday, Palantir Technologies soared 30% after earnings.

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

Top 3 Smart Pharma Picks for Good Investments

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

Weight loss injection to be made available in UK within weeks

Weight loss injection to be made available in UK within weeks

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity

The Guardian - UK

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

Iron Condor Alert: LLY Stock Could Net 40% In 4 Weeks

Iron Condor Alert: LLY Stock Could Net 40% In 4 Weeks

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

Will weight loss drugs kill the fast food business?

Will weight loss drugs kill the fast food business?

Many firms see the dire forecasts as ‘overblown’ but they know they will have to adapt products to make ‘every bite counts’

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

Eli Lilly Launches Unique Website Connecting Patients to Obesity Care+

Eli Lilly launches LillyDirect, a one-of-a-kind website connecting patients seeking obesity treatment to doctors and its weight-loss drug. Streamlining hea...

Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of diabetes and obesity

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

Eli Lilly Stock: Buy or Sell?

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Get all your
news in one place.

100's of premium titles.
One news app.

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

The Independent UK

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

Which Weight Loss Drug Is Best And Safest? Here’s What Sets Them Apart

Earlier this month, the FDA approved Eli Lilly's Zepbound, a drug similar to its diabetes drug Mounjaro but specifically advertised for weight loss.

International Business Times

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

The Independent UK

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Will Weight Loss Drugs be the Next Big Thing?

Several pharmaceutical companies are racing to develop obesity drugs and tap into a surge in consumer demand for the extremely profitable drugs. Sales of Eli Lilly’s (LLY ) diabetes drug Mounjaro, just approved by the U.S. Food and Drug Administration (FDA) for obesity in the U.S., hit $1.41 billion in...

1 … 21 22 23 24

People

Dipanjan BanchurSince

Chris Kempczinski

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

389,185 stories

142,261 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play